ScholarIQanswers from OpenAlex

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications

PaperCitations, authors & open-access status

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications have?

ScholarIQcitation count

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications has 170 citations in the OpenAlex counts ScholarIQ stores.

When was Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications published?

ScholarIQyear

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications has 2014 year in the ScholarIQ index.

What is the open-access status of Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications?

ScholarIQoa status

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications has closed oa status in the ScholarIQ index.

What is the DOI of Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications?

ScholarIQdoi

The DOI for Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications is on the source record.

What is the PMID of Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications?

ScholarIQpmid

The PMID for Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications is on the source record.

What is the OpenAlex record for Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications?

ScholarIQopenalex

The OpenAlex for Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial